Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease

Janssens, Peter; Decuypere, Jean Paul; Rechter, Stéphanie De; Breysem, Luc; Giel, Dorien Van; Billen, Jaak; Hindryckx, An; Catte, Luc De; Baldewijns, Marcella; Claes, Kathleen; Wissing, Karl Martin; Devriendt, Koen; Bammens, Bert; Meyts, Isabelle; Torres, Vicente E.; Vennekens, Rudi; Mekahli, Djalila

doi:10.1016/j.ekir.2021.03.893

Cited by 15 publications

(16 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Regarding MCP-1, it was significantly augmented in patients with CKD compared to controls. In line with this study, other researches showed that MCP-1 levels increased in chronic kidney diseases in children 29 and adults 30 . In addition, deletion of MCP-1 has reduced glomerular and interstitial infiltration of macrophages and histological damage in several models of renal diseases.…”

Section: Discussionsupporting

confidence: 90%

Measurement of Inflammation-Related Biomarkers in Different Chronic Kidney Diseases in Humans: Role of Aging and Gender?

Ahmad

Ajeel

Aldabbagh

2021

imjm

View full text Add to dashboard Cite

INTRODUCTION: Chronic kidney disease (CKD) is a worldwide health problem which becomes a substantial emerging cause of morbidity. The inflammation can be resulted via different mechanisms in different kidney diseases including the imbalance of proinflammatory/anti-inflammatory biomarkers levels. This study aimed to measure the level of physiological bioactive substances as inflammation-related biomarkers in different CKD and to investigate whether gender or aging is critical in these measurements. MATERIALS AND METHODS: 84 persons (19 healthy, 29 chronic glomerulonephritis, 26 diabetic nephropathy, 6 benign nephrosclerosis, 4 lupus nephritis) were enrolled in this study. The inflammation progression degree in CKD was estimated by measuring the plasma level of neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein 1 (MCP1), and clusterin (CLU) using ELISA. Serum total protein, urea and creatinine were measured using an automatic analyzer. RESULTS: Plasma level of urea and creatinine was increased while total protein level was decreased in all the patients compared to control participants. The level of NGAL, MCP1 and CLU was significantly increased in all the kidney diseases compared to controls. In addition, there were no differences in the level of inflammation-related markers between women and men. Moreover, the levels of inflammatory markers were increased in the kidney diseases regardless of the age difference. CONCLUSIONS: This study showed that the physiological bioactive substances NGAL, MCP1 and CLU can be increased in renal pathologies and considered as good indicators of progression of inflammation in chronic kidney diseases, with no role of gender and age in their increment plasma levels.

show abstract

Section: Discussionsupporting

confidence: 90%

Measurement of Inflammation-Related Biomarkers in Different Chronic Kidney Diseases in Humans: Role of Aging and Gender?

Ahmad

Ajeel

Aldabbagh

2021

imjm

View full text Add to dashboard Cite

show abstract

“…Cytokines may be affected heterogeneously by the diseases. For instance, MCP-1 correlates negatively with chronic active hepatitis B [ 62 ] but positively with autosomal dominant polycystic kidney disease (ADPKD) [ 63 ]. One expects a person with these two diseases to have contradicting effects on MCP-1, thus exhibiting a misleading regular level of MCP-1.…”

Section: Resultsmentioning

confidence: 99%

Potential of Point-of-Care and At-Home Assessment of Immune Status via Rapid Cytokine Detection and Questionnaire-Based Anamnesis

Jamaludeen

Beyer

Billing

et al. 2021

Sensors

View full text Add to dashboard Cite

Monitoring the immune system’s status has emerged as an urgent demand in critical health conditions. The circulating cytokine levels in the blood reflect a thorough insight into the immune system status. Indeed, measuring one cytokine may deliver more information equivalent to detecting multiple diseases at a time. However, if the reported cytokine levels are interpreted with considering lifestyle and any comorbid health conditions for the individual, this will promote a more precise assessment of the immune status. Therefore, this study addresses the most recent advanced assays that deliver rapid, accurate measuring of the cytokine levels in human blood, focusing on add-on potentials for point-of-care (PoC) or personal at-home usage, and investigates existing health questionnaires as supportive assessment tools that collect all necessary information for the concrete analysis of the measured cytokine levels. We introduced a ten-dimensional featuring of cytokine measurement assays. We found 15 rapid cytokine assays with assay time less than 1 h; some could operate on unprocessed blood samples, while others are mature commercial products available in the market. In addition, we retrieved several health questionnaires that addressed various health conditions such as chronic diseases and psychological issues. Then, we present a machine learning-based solution to determine what makes the immune system fit. To this end, we discuss how to employ topic modeling for deriving the definition of immune fitness automatically from literature. Finally, we propose a prototype model to assess the fitness of the immune system through leveraging the derived definition of the immune fitness, the cytokine measurements delivered by a rapid PoC immunoassay, and the complementary information collected by the health questionnaire about other health factors. In conclusion, we discovered various advanced rapid cytokine detection technologies that are promising candidates for point-of-care or at-home usage; if paired with a health status questionnaire, the assessment of the immune system status becomes solid and we demonstrated potentials for promoting the assessment tool with data mining techniques.

show abstract

“…45 Increase in tubular MCP-1 excretion is an early event in pediatric ADPKD population and an early marker of disease severity. 46 Furthermore, urinary MCP-1 in adult patients with ADPKD provided a predictive prognostic value when added to other biomarkers that reflect tubular damage such as β2-microglobulin. 47,48 Urinary T cells correlated moderately with renal function decline in a small cohort of ADPKD patients providing further evidence that this novel marker could be a candidate of disease activity in ADPKD.…”

Section: Discussionmentioning

confidence: 99%

Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease

Jones¹,

Mkhaimer²,

Rangel³

et al. 2022

Kidney360

Self Cite

View full text Add to dashboard Cite

Background: Autosomal dominant polycystic kidney disease (ADPKD) has phenotypic variability only partially explained by established biomarkers that do not readily assess pathologically important factors of inflammation and kidney fibrosis. We evaluated asymptomatic pyuria, a surrogate marker of inflammation, as a biomarker for disease progression. Methods: We performed a retrospective cohort study of adult patients with ADPKD. Patients were divided into asymptomatic pyuria (AP) and no pyuria (NP) groups. We evaluated the effect of pyuria on kidney function and kidney volume. Longitudinal models evaluating kidney function and kidney volume rate of change with respect to incidences of asymptomatic pyuria were created. Results: There were 687 included patients (347 AP, 340 NP). The AP group had more female (65.1% vs 49.4%). Median age at kidney failure was 86 and 80 years in NP and AP groups, respectively (Log-rank, p=0.49) for patients with Mayo Imaging Class (MIC)1A-1B as compared to 59 and 55 years for patients with MIC1C-1D-1E (Log-rank, p=0.02). Compared to NP group, the rate of kidney function (ml/min/1.73m2/year) decline shifted significantly after detection of asymptomatic pyuria in models including all patients (-1.48, p<0.001), MIC 1A-B patients (-1.79 , p<0.001), MIC 1C-1D-1E patients (-1.18, p<0.001), and PKD1 patients (-1.04, p<0.001). Models evaluating kidney volume rate of growth showed no change after incidence of asymptomatic pyuria as compared to NP group. Conclusions: Asymptomatic pyuria is associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene, cystic burden, and cystic growth. These results support asymptomatic pyuria as an enriching prognostic biomarker for the rate of disease progression.-

show abstract

Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease

Cited by 15 publications

References 54 publications

Measurement of Inflammation-Related Biomarkers in Different Chronic Kidney Diseases in Humans: Role of Aging and Gender?

Measurement of Inflammation-Related Biomarkers in Different Chronic Kidney Diseases in Humans: Role of Aging and Gender?

Potential of Point-of-Care and At-Home Assessment of Immune Status via Rapid Cytokine Detection and Questionnaire-Based Anamnesis

Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease

Contact Info

Product

Resources

About